Gold prices cool after hitting over 2-week high on Fed independence fears
Investing.com - H.C. Wainwright has reiterated a Buy rating and $15.00 price target on Lisata Therapeutics, Inc (NASDAQ:LSTA) following the company’s second quarter financial results and pipeline updates. According to InvestingPro data, this target represents significant upside from the current trading price of $2.40, though the stock has declined about 19% year-to-date.
Lisata reported second-quarter earnings per share of ($0.54), beating both the analyst estimate of ($0.66) and consensus of ($0.65). The company ended the quarter with approximately $22 million in cash, which management believes provides runway into the fourth quarter of 2026 for all ongoing and proposed trials. InvestingPro analysis shows the company maintains a strong current ratio of 5.77 and holds more cash than debt, though it’s currently burning through cash rapidly. Get access to 7 more key ProTips and detailed financial metrics with InvestingPro.
The company continues advancing its lead candidate certepetide, with several upcoming milestones. For the ASCEND Phase 2b study in metastatic pancreatic ductal adenocarcinoma (mPDAC), final data from Cohorts A and B are expected later this year. Lisata has already received FDA agreement on key elements for a Phase 3 protocol and has begun preparations for trial initiation, pending additional capital.
The BOLSTER Phase 2a trial, evaluating certepetide in combination with standard-of-care treatments in first-line and second-line cholangiocarcinoma (CCA), has completed enrollment in the first-line cohort nearly six months ahead of schedule. This acceleration has moved the anticipated topline data readout to the fourth quarter of 2025.
The CENDIFOX Phase 1b/2a open-label study, which is testing certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers, continues to progress steadily, with data expected in the coming months according to management.
In other recent news, Lisata Therapeutics Inc. reported its Q2 2025 earnings, exceeding expectations with an earnings per share (EPS) of -0.54 against the anticipated -0.64. This represents a positive surprise of 15.63%. The company also reported revenue of $70,000, derived from a research license with Catalent Inc (NYSE:CTLT). Despite this earnings beat, the company faced a decline in stock value, which was attributed to complex investor sentiment and broader market conditions. These developments highlight the company’s recent financial performance and its ongoing engagements in research licensing. Investors and analysts are closely monitoring how these factors might influence future performance. The earnings results were a key focus for stakeholders seeking insights into the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.